GelTex To Discuss Anti-Obesity Collaboration With Roche, CEO Says
Executive Summary
GelTex could begin discussions with Roche on a development agreement to improve Roche's anti-obesity therapy Xenical (orlistat), GelTex CEO Mark Skaletsky told financial analysts at the Hambrecht & Quist Health Care Conference in San Francisco Jan. 12.
You may also be interested in...
GelTex Eyes Polyamines/Polymers Combination From SunPharm Acquisition
GelTex, developer of polymer-based pharmaceuticals, will test for complementary effects of combining polyamines and polymers following its acquisition of Jacksonville, Fla.-based SunPharm.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011